CDH17 and glioblastoma: Caution is therefore mandatory when interpreting results for cadherin expression and its role as EMT biomarkers in glioblastoma, as proof of a cadherin switching process remains elusive in glioblastoma and cadherin expression contribution to glioma progression is still unclear.